We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Astrazeneca Plc | LSE:AZN | London | Ordinary Share | GB0009895292 | ORD SHS $0.25 |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-38.00 | -0.32% | 11,988.00 | 12,014.00 | 12,018.00 | 12,144.00 | 11,882.00 | 12,070.00 | 2,340,814 | 16:35:09 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 45.81B | 5.96B | 3.8415 | 31.28 | 186.27B |
Date | Subject | Author | Discuss |
---|---|---|---|
15/11/2023 17:07 | A failure is a failure, simples! | dudishes | |
15/11/2023 16:26 | Blackhorse23 filtered. | faz | |
15/11/2023 16:03 | Could certainly do with some good news here. Hitting the 2023 lows now 😳 | philanderer | |
15/11/2023 10:27 | Money moving to APH , excellent healthcare dividend company | blackhorse23 | |
15/11/2023 06:36 | WRT reaction, smallpox jab had 1 in 100K reactions, in a group of Royal Navy men. Mr Watkins, Welsh, was found to have a hole in his heart. Mr Evershed was found to have bowel cancer. In both cases, 19yrs of age. Both of these issues are recorded at the Journal. | dudishes | |
14/11/2023 10:05 | About time all the directors took their companies jabs and left to rot in jail | bob reno | |
10/11/2023 15:42 | £100 chart support about to go..... £97 next stop. | philanderer | |
10/11/2023 09:56 | 2020 pre roll out ........... "It was pure evil they received permission to administer the unproven vaxxeen to children !!!" 10-15yrs is the normal trial period .....these jabs by passed the animal trials ffs !! On Oct. 16, Pfizer’s CEO indicated the company would likely file for FDA Emergency Use Authorization for its experimental BNT162b2 vaccine in late November. That statement came three days after Pfizer announced that it had received FDA permission to administer the unproven vaccine to children as young as 12, becoming the first company in the U.S. to include young participants in Phase 3 trials. In the UK, Oxford and AstraZeneca gained approval to test their vaccine in children aged 5-12 back in May, a couple of months before two of their adult clinical trial participants developed transverse myelitis. | bob reno | |
10/11/2023 08:34 | Money moving to APH | blackhorse23 | |
09/11/2023 12:53 | Settled for 3pts. cheers | dudishes | |
09/11/2023 12:16 | 10480, another good bet imo? | dudishes | |
09/11/2023 12:06 | We have licensed a weight loss drug! From a Chinese company though. It's in phase one trials , taken in pill form and based on research to date low on side effects and effective at low doses. | smcni1968 | |
09/11/2023 11:35 | https://www.londonst | blackhorse23 | |
09/11/2023 11:16 | Just two that I know of. | dudishes | |
09/11/2023 10:23 | Nicey bouncey! 10449 for 142pts. Difficult to make this up? | dudishes | |
09/11/2023 09:10 | Stop chatting, get stuck in. 10307! Dinner money? | dudishes | |
09/11/2023 08:24 | News Highlights: Top Company News of the Day 09 November 2023 - 08:15AM Dow Jones News AstraZeneca Ups Core EPS Guidance Despite Profit Miss AstraZeneca raised its full-year guidance for core earnings per share and total revenue excluding Covid-19 medicines despite a lower third-quarter profit that missed forecasts. | adrian j boris | |
09/11/2023 07:12 | Updated guidance on non Covid revenue from high single digit growth to low teens growth is excellent news.Development pipeline of drugs also looks very promising.See where the market expectations were this morning, but I think we will get an significant uptick IMO. | our haven | |
09/11/2023 07:10 | As with flu jab, you are warned. If reaction occurs, it is up to relevant health services to take care of the patient. Compensation, I expect, will be denied | dudishes | |
09/11/2023 00:27 | Oxford AstraZeneca Covid jab was ‘defective&rsq | philanderer |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions